AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00049114
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01414777
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo or ondansetron 8mg IV will be administered prior to placement of the spinal anesthetic
Trial: NCT00198952
Drug: DietPro
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00198952
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00790218
Drug: CF102
RxNorm normalized name: Cannabinoid Receptor Agonist CF102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF102 capsules twice daily by mouth
Trial: NCT00398320
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 850 mg/m2 by mouth twice a day for days 1-14 oa a 21 day cycle
Trial: NCT01740323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily placebo for 6 weeks
Trial: NCT01332695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match
Trial: NCT02496520
Drug: Chemotherapy as needed by the patient´s tumor and stage
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01137526
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take study drug once daily for 12 weeks
Trial: NCT00234169
Drug: VTP195183
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VTP195183: 60mg/m2 orally daily G-CSF: 10mcg/kg/day subcutaneously Provision is made for dose reduction of VTP195183 in the event of unexpected dose-limiting toxicities G-CSF10mcg/kg/day will commence on day 1 and will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first.~Patients will be treated with VTP195183 alone at 60mg/m2/day from day 1 to day 7. On day 8 VTP195183 will be continued and G-CSF10mcg/kg/day will be added. VTP195183 plus G-CSF will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first.
Trial: NCT02183233
Drug: Eschscholtzia Californica
RxNorm normalized name: Eschscholzia californica extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183233
Drug: Eschscholtzia Californica Placebo
RxNorm normalized name: Eschscholzia californica extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03364309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02700828
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 \* 0,5 mg/kg /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
Trial: NCT02700828
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 \* 2 ml isotonic sodium chloride solution /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
Trial: NCT02394834
Drug: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Trial: NCT02394834
Drug: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Trial: NCT00516165
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pills taken daily in a 42-day cycle (6 weeks). Cycles will be repeated every 42 days
Trial: NCT02464722
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mcg/kg iv loading dose of remifentanil over a period of 10 minutes. Later, an infusion was started at the rate of 0.4-0.8mcg/kg/min.
Trial: NCT02464722
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.
Trial: NCT00258323
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2/d IV continuous infusion x 4 days
Trial: NCT01789203
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized 2:1 placebo comparator to active comparator, Cipro.
Trial: NCT03676140
Drug: Azithromycin on Day 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 1
Trial: NCT03676140
Drug: Azithromycin on Day 8
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 8
Trial: NCT02028884
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
Trial: NCT02922179
Drug: Long- and intermediate- acting insulins
RxNorm normalized name: Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alone or in combination with metformin, short-acting insulin, or second-generation sulfonylurea
Trial: NCT02465203
Drug: Previous treatment in DEB025 study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up after DEB025 active study
Trial: NCT04188145
Drug: Fluoropyrimidine
RxNorm normalized name: Fluoropyrimidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Option 1: Capecitabine 1250 mg/m2 twice daily (i.e. 2500 mg/m²/d) (D1 to D14, D1 = D22) For frail patients according to investigator evaluation capecitabine dose may be reduced to 1000 mg/m2 twice daily (2000 mg/m²/d).~Or Option 2: Capecitabine 625 mg/m2 twice daily (i.e. 1250 mg/m²/d) (D1 to D21, D1 = D22) Or Option 3: LV5FU2 simplified (folinic acid 200 mg/m² (or Elvorin 400 mg/m²) IV during 2h followed by 5-FU bolus IV of 400 mg/m² during 10 min and IV continuous 5-FU at 2400 mg/m² during 46h). (D1=D15).
Trial: NCT01975454
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin (130 mg/m2) was given intravenously (iv) for at least 2 h on day 1; Capecitabine (1000 mg/m2) was given orally, twice daily on days 1-14. Each cycle was 21 days. Cycles were repeated until disease progression or unacceptable toxicity.
Trial: NCT01975454
Drug: Herbal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLBZT based herbal decoction administered orally twice a day
Trial: NCT00273455
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02004613
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline administration matching dexmedetomidine rate of infusion
Trial: NCT02327078
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT00984282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 tablets) will be administered orally, twice daily (approximately every 12 hours).
Trial: NCT02687646
Drug: Adult Allogeneic Mesenchymal cells from adipose tissue.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study treatment consists of Mesenchymal Stem Cell (MSC) derived from donors adipose tissue and expanded in vitro in a specific medium with platelet lysate without addition of animal derived products.~Subjects will receive four sequential IV dose of Mesenchymal stem cells.~Sequential doses:~Day 1: 0.7-1 x 106 MSC / kg Day 4: 0.7-1 x 106 MSC / kg Day 11: 0.7-1 x 106 MSC / kg Day 18: 0.7-1 x 106 MSC / kg
Trial: NCT01520298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the control group, a total of 100 mLs of 0.9% sodium chloride will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mL/min). A beyond use expiration of 6 hours will be placed on the container. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
Trial: NCT01520298
Drug: Acetaminophen IV
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the treatment group, a total of 100 milliliters (mLs) of acetaminophen (1000 mg) will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mLs/min). A beyond use expiration of 6 hours at room temperature will place on the container, as recommended by the manufacturer. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
Trial: NCT00414128
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous cyclophosphamide, 15mg/kg with dose reductions according to age and renal function, for 3-6 months (6-10 doses total)
Trial: NCT04329832
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in the azithromycin arm will receive azithromycin 500 mg on day 1 plus 250 mg daily on days 2-5 (may be administered intravenously per clinician preference). If the patient has already received azithromycin prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.
Trial: NCT00990106
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04729764
Drug: GP681 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Designed as 5 dose groups (20mg, 40mg, 60mg, 80mg, 120mg), the starting dose group (20mg) 8 subjects (including 2 placebo), each other 10 subjects (including Placebo (2 cases), male and female.
Trial: NCT00979771
Drug: GSK706769
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg GSK706769 twice daily orally (BID) for 28 days
Trial: NCT00979771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK706769 matched-placebo twice daily orally (BID) for 28 days
Trial: NCT01223183
Drug: hypertonic saline (7%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single treatment by inhalation
Trial: NCT01223183
Drug: isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single treatment by inhalation
Trial: NCT02605421
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide by IV once daily for 4 doses on Days -5, -4, -3 and -2. Given as part of Consolidation Course #1 along with Thiotepa.
Trial: NCT01360190
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fluoxetine 20 mg. daily
Trial: NCT01769781
Drug: GnRH analog alone
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment for three months with GnRH analog (leuprolide acetate) alone
Trial: NCT00370565
Drug: Inhaled Human Insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03688828
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg bid
Trial: NCT02457312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets which look identical to the letrozole tablets for 7 days before suction evacuation
Trial: NCT02601651
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline group will receive an intravenous normal saline bolus at induction followed by continuous infusion of normal saline until the tracheal extubation
Trial: NCT00648557
Drug: Levothyroxine Sodium Tablets 200 mg
RxNorm normalized name: levothyroxine sodium Chewable Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x200mcg, single dose fasting
Trial: NCT00648557
Drug: Synthroid Tablets 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x200mcg, single dose fasting
Trial: NCT03451123
Drug: FET PET/MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FET PET/MRI scan before and after surgery
Trial: NCT03274856
Drug: GLWL-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 3 capsules, twice a day
Trial: NCT03274856
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 3 capsules, twice a day
Trial: NCT03688828
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5g bid
Trial: NCT00948428
Drug: Aldara™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
Trial: NCT00948428
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream vehicle matching Generic imiquimod dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
Trial: NCT00463619
Drug: Retarded release phosphatidylcholine
RxNorm normalized name: phosphatidylcholine, soybean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2g phosphatidylcholine, given QTD
Trial: NCT02290041
Drug: Infusion of placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of placebo (weeks 0-4-8-20)
Trial: NCT04096287
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose
Trial: NCT01495195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: microcrystalline cellulose
Trial: NCT02814175
Drug: methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03084601
Drug: Calcium Hydroxide, Iodoform, paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mixture of calcium hydroxide and iodoform
Trial: NCT03084601
Drug: 3-mixtatin
RxNorm normalized name: HISTATIN 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-mixtatin mixture of ciprofloxacin, metronidazole, cefixime, and simvastatin
Trial: NCT00413296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, Tablets, no active ingredient in the tablets, (1-6tablets/day)for 12 wks in the 2nd phase of the study.
Trial: NCT03349684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose matching placebo, oral
Trial: NCT01772056
Drug: Placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group: on treatment with twice weekly on consecutive days vehicle cream for 16 weeks or at relapse.
Trial: NCT01118689
Drug: MLN0128
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN0128 administered orally once daily for 28 days
Trial: NCT04463264
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 tablet every 6 hours for 14 days) orally with food (P.O.).
Trial: NCT01913002
Drug: LX4211 800 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01913002
Drug: LX4211 2000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01913002
Drug: LX4211 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00656864
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02744196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution will look identical to the Acellbia solution.
Trial: NCT02744196
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01462617
Drug: GSK2269557
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Drug
Trial: NCT02767128
Drug: Shohl's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01462617
Drug: GSK2269557 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Drug
Trial: NCT00303485
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po monthly for 6 months
Trial: NCT00303485
Drug: Vitamin D and calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT00303485
Drug: ibandronate [Bonviva/Boniva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg po monthly for 6 months
Trial: NCT01235234
Drug: CF101
RxNorm normalized name: CF101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally q12h
Trial: NCT00597688
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mucosal application of placebo gel
Trial: NCT04173845
Drug: Tianqi Pingchan Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianqi Pingchan Granule are given twice a day
Trial: NCT04173845
Drug: Tianqi Pingchan Granule Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianqi Pingchan Granule Placebo
Trial: NCT03686384
Drug: SVT-15652
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 vial twice daily
Trial: NCT03686384
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 vial twice daily
Trial: NCT00390039
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN Placebo q1h PRN
Trial: NCT00390039
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Placebo q3h PRN
Trial: NCT00390039
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN Placebo q3h PRN
Trial: NCT03536559
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is liquid with identical color and taste
Trial: NCT01770236
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the IV acetaminophen group will receive IV acetaminophen (1000 mg every 6 hours for adults and weight-based for any patient under 50 kg)instead of an On-Q pain pump catheter.
Trial: NCT01052506
Drug: BIIB033
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, escalating doses of BIIB033 (8 cohorts IV, 1 cohort SC)
Trial: NCT01052506
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo comparator (8 cohorts IV, 1 cohort SC)
Trial: NCT00374387
Drug: minipill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00811681
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a placebo administered orally once a day after the first visit and for a total of 2 years.
Trial: NCT04780412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal placebo pills given 90-120 minutes before an elective caesarian section.
Trial: NCT00197899
Drug: E. Coli endotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03425539
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules are identical in appearance to the lucerastat capsules, and contain inactive excipients; 4 capsules b.i.d.; dose adjusted for renal function.
Trial: NCT02040844
Drug: Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02265718
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 - matching tablet taken once on Day 0 and once on Day 28
Trial: NCT00629811
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference therapy was Placebo (vehicle). On Day 0, the four sites randomised to receive Placebo were administered with a 100μL intradermal injection of Placebo.~Subjects in Group 2 were dosed again on Day 0 at 10 to 30 minutes after wound closure.~Subjects in Group 1 were dosed again on Day 1 at 24 (+/-4) hours after initial administration of drug.
Trial: NCT00477412
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00477412
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00477412
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04244591
Drug: methylprednisolone therapy
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 40 mg q12h for 5 days
Trial: NCT00237341
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01620814
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00186810
Drug: Busulfan, Cyclophosphamide, Horse ATG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transplant recipients received a myeloablative conditioning regimen of cyclophosphamide, Anti-Thymocyte Globulin (horse), and Busulfan. Cyclosporine and methotrexate were administered for GVHD prophylaxis.